Dangerous AIDS Policy Wall Street Journal - In Thailand and India, for example, locally produced Aids drugs are often of such low quality that they're actually fueling drug resistance. ...
The Personal Price of AIDS DiversityInc.com (subscription) - ... dreamed that drug abuse, a horror in and of itself, would lead to an even greater horror in HIV and AIDS. But it did--and Pat paid the ultimate price, ...
Providing Medicines For The Poor Chemical & Engineering News - By creating incentives to provide important pharmaceutical innovations at low prices, HIF would easily pay for itself. Through lower drug prices, ...
Editorials, Opinion Pieces Respond to World AIDS Day Kaiser network.org, DC - According to the editorial, "Those who learn they are infected could stop sharing contaminated drug needles and adopt safer-sex practices. ...
Abbott faces more litigation over AIDS drug The Associated Press - Aug 3, 2008 SAN FRANCISCO (AP) ? When Abbott Laboratories Inc. hiked up the price of a popular AIDS drug by 400 percent in 2003, executives prepared for the inevitable ...ABT
[CITATION] Against the Odds: The Story of AIDS Drug Development, Politics and Profits. PS Arno, KLFN York, HC Publishers - Journal of Mental Health Administration, 1997 - Association of Behavioral Healthcare Management [etc.] -
Barriers to Use of Free Antiretroviral Therapy in Injection Drug Users - SA Strathdee, A Palepu, PGA Cornelisse, B Yip, MV … - JAMA, 1998 - Am Med Assoc ... HIV/AIDSDrug Treatment Program. ... Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS. ...
Low antituberculosis drug concentrations in patients with AIDS - CA Peloquin - The Annals of Pharmacotherapy, 1996 - Harvey Whitney Books ... Research Articles. Low antituberculosis drug concentrations in patients with AIDS. CA Peloquin, AT Nitta, WJ Burman, KF Brudney, Miranda ...
Source: Google Scholar
Annan pushes AIDS drug makers to lower prices
UNITED NATIONS - U.N. Secretary-General Kofi Annan encouraged executives from nine drug companies on Monday to lower prices of AIDS medicines and step up efforts to develop AIDS drugs and diagnostics for children.
Annan for the first time included generic drug makers in his latest in a series of meetings with top drug makers at U.N. headquarters over the past five years.The meetings aim to encourage the pharmaceutical firms to broaden access to AIDS drugs, care and support services in low- and middle-income countries.While the executives had helped, the AIDS epidemic was "still outpacing our efforts, and we need to work together in a broad partnership to step up the response," he said.At his request, the officials agreed to review the prices of existing and new HIV medications and diagnostics to make them more affordable, accessible and appropriate for use in low- and middle-income countries, Annan said.
They also pledged to give greater priority to developing pediatric formulations of HIV medications and diagnostic tools for children.
Attending the meeting were Stephen Saad, group chief executive of South Africa's Aspen Pharmacare Holdings Ltd.; Chairman P. V. Ramprasad Reddy of Indian drug maker Aurobindo Pharma Ltd.; Gary Cohen, executive vice-president of U.S. firm Becton Dickinson & Co.'s BD Medical unit, and Peter Dolan, chief executive officer of U.S.-based Bristol-Myers Squibb Co..
Also attending along with Annan and U.N. officials involved in the fight against AIDS were Jean-Pierre Garnier, chief executive officer of British drug maker GlaxoSmithKline Plc; B.P.S. Reddy, founder of Indian pharmaceutical firm Hetero Drugs Ltd.; Christine Poon, vice chairman of U.S.-based Johnson & Johnson; U.S.-based Merck & Co. Inc. Chief Executive Officer Richard Clark, and Malvinder Mohan Singh, chief executive officer of India's Ranbaxy Laboratories Ltd..
